What’s new?
- In this focused review on vancomycin TDM, the altered pharmacokinetic
parameters in special groups of patients including renal failure,
hepatic failure, critically ill patients, burn injuries, IV drug
users, obese and morbidly obese patients, and pregnant or
breastfeeding women have been considered.
- Recommendations on individualized pharmacokinetic assessments have
been provided in these special groups of patients with altered
pharmacokinetic characteristics.
- Using different pharmacokinetic parameters for the purpose of
vancomycin TDM has been discussed in detail with emphasis on their
pros and cons.